The relation betw een insulin resistance/ hyperinsulinemia and cardiovascular disease may be re lated to one of the cardiovascular effects of insulin. In acute experiments in humans, systemic euglycemic hyperinsulinemia induced vasodilation in skeletal muscle. Furthermore, the sympathetic nervous system is acti vated, although this does not lead to increase in blood pressure (BP). We hypothesized that insulin could induce vasodilation either by reduction of a-or by augmentation of p-adrenergic responsiveness. The effect of insulin in fusion into the brachial artery (regional forearm hyperin sulinemia; venous insulin concentration -500 pM) on forearm blood flow (FBF: plethysmography) was studied. Responses to the a-adrenoceptor-mediated vasoconstric tor norepinephrine (NE: once with and once without the padrenoceptor antagonist propranolol, 2 x n = 12; 9 par ticipated in both), and to the p-adrenoceptor-mediated vasodilator isoproterenol (n = 12) were measured before and during local hyperinsulinemia. Time/control studies (n = 6 ) were performed. Insulin alone induced vasodila
tion, as indicated by an increase in FBF'ratio (infused/ control arm) from 1 .2 ± 0 .1 to 1 .6 ± 0 .2 , p = 0.009. Increasing dosages of N E (1.25 to 240 ng * d l' 1 • m l ' 1) induced vasoconstriction that was more pronounced dur ing concomitant propranolol infusion (p < 0 .0 0 1 ), indicat ing a dose-dependent vasodilatory component in the ef fect of NE. Isoproterenol (ISO 0.03 to 10 ng * dl~* ' ini'"1), a pure p-adrenoceptor agonist, induced vasodilation. The percentage changes of FBF-ratio during NE + propran olol were similar and not significantly different before and during hyperinsulinemia. The same was true o f the re sponse to N E alone and the response to ISO. Neither was the intrinsic p-agonist component of N E influenced by insulin. Repeated NE infusion showed no time-or vehicle effect. We conclude that regional hyperinsulinemia in the physiological range induces local vasodilation in the skel etal muscle vascular bed, but this vasodilation is not me diated through modulation of a-or p-adrenergic respon siven ess. Key Words: Insulin-a-A d ren ocep tor-p-Adrenoceptor-V as odilation.
Hyperinsulinemia as a counterpart of insulin re sistance is a prominent feature of associated cardio vascular risk factors as hypertension, obesity, dyslipidemia, and non-insulin-dependent diabetes mellitus (1,2). The nature and significance of this association, an issue of considerable pathophysio logical importance, is still unclear but may be re lated to the cardiovascular effects of insulin. Be sides its key role in the regulation of carbohydrate metabolism (3), insulin has important cardiovascu lar effects (4, 5) . Despite earlier reports that insulin was in itself capable of inducing hypertension (6), most recent reports have failed to confirm this (7, 8) . Indeed, in acute experiments in healthy subjects (9,10) as well as in patients with hypertension (11), insulin has been shown to induce a vasodilator ef fect and not to increase systemic blood pressure (BP). Furthermore, several groups of researchers, including ourselves, have shown that during acute hyperinsulinemia the sympathetic nervous system is activated (9,11-13).
The mechanism of insulin's effect on vascular tone has not yet been clarified (4), but an interaction with the autonomic nervous system seems obvious because insulin-induced stimulation of the sympa thetic nervous system does not lead to increases in BP, at least not in acute experiments. Thus, insulininduced vasodilation could be explained by a de creased sensitivity of the vascular bed to a-adrenergic stimuli or an increased responsiveness to (3adrenoceptor agonists. Indeed, various investiga tors have reported a change in responses to adre nergic stimuli deemed to be a modulatory effect of insulin. The reported results, however, are ex tremely controversial and show various differences in design: Studies in humans versus in animal (14, 15) , studies with systemic hyperinsulinemia (euglycemic clamp technique) versus studies with re gional hyperinsulinemia (16, 17) , systemic adminis tration of vasoactive drugs versus local administra tio n ( 1 8 ,1 9 ) , and g rea t v a r ie ty in drugs administered: norepinephrine (NE) ( In the present study, we used the perfused fore arm technique to investigate whether acute hyper insulinemia affected vascular a-or p-adrenoceptor responsiveness in humans. Studying these two as pects together may be advantageous, because at dif ferent levels significant interactions and cross-talks do exist: Both endogenous catecholamines NE and epinephrine exhibit a-and (3-adrenoceptor affinity.
Furthermore, stimulation of presynaptic a-and (3-adrenoceptors inhibits and stimulates NE release from sympathetic nerve endings, respectively (31). Finally, an eventual effect of insulin modulating the a-adrenoceptor-mediated vasoconstriction could be counterbalanced by a change in (3-adrenoceptor sensitivity, Our results convincingly show that in sulin has local vasodilator properties itself but does not affect the responsiveness to a-or (3-adrenocep tor stimulation.

METHODS Subjects
In all, 42 studies were performed in 33 healthy subjects (16 women, 17 men), aged 19-32 years (mean ± SD, 23 ± 3 years). All were normotensive [mean office BP after 5-min rest in the supine position: systolic BP (SBP) 125 ± 11 mm Hg and diastolic BP (DBP) 75 ± 8 mm Hg], and normoglycemic and had a normal weight [body mass in dex (BMI) 22.5 ± 1.7 kg ■ m -2 ]. All subjects had a neg ative family history of diabetes mellitus and hyperten sion. The participants were recruited by advertisement and received a small remuneration. All gave written in formed consent. The experimental protocol was ap proved by the local ethics committee.
Measurements
Forearm volume was measured by water displacement. Forearm blood flow (FBF) was measured simultaneously in both forearms by mercury-in-silastic strain-gauge ve nous occlusion plethysmography. The elbows and wrist were supported at or just above heart level. Strain gauges were attached around the forearm at the level of the max imal diameter. One minute before the start of the FBF measurements, a pediatric cuff around the wrists was in flated to 100 mm Hg above the SBP level to ensure that the measurements referred only to the skeletal muscle vascular bed of the forearm. The collecting cuff around the upper arm was inflated to a supravenous pressure of 40 mm Hg during eight heart cycles with the Hokanson E20 rapid cuff inflator (ECG-triggered). This cycle was repeated three to four times each minute. The strain gauges were connected with Hokanson's EC4 plethysmographs, and FBF was determined in mm/100 ml forearm volume per minute from the mean vertical deflection per minute divided by a 1% electrical calibration signal. FBF was expressed as milliliters per minute per deciliter of forearm volume, In addition, the ratio of the FBF in the infused arm to that in the control arm was calculated for each measurement (FBF ratio).
All experiments were performed in a temperaturecontrolled room (22°-24°C). Before, after 30 min, and af ter 60 min of local hyperinsulinemia, arterial and venous blood samples were taken for determination of glucose and insulin. Plasma glucose was measured by the glucose oxidation method (BeckmannR Glucose analyzer 2, Beckman Instruments, Fullerton, CA, U.S.A.); plasma insulin concentration was measured by a double-antibody in-house radioimmunoassay (RIA) with an interassay co efficient of variation of 6 .2 %. 
Protocols
5269-129) to a Hewlett Packard 78353B monitor. Mean arterial pressure (MAP) was determined by an electroni cally integrated area under the brachial arterial pulsewave form. The line was kept patent with saline infusion (3 ml/h with 2 U heparin/ml added). The dosages of drugs that administered were calculated per deciliter of forearm volume (ng • dl" 1 • min" 1). Moreover, a catheter (Venflon, 20 gauge, 32 mm) was retrogradely inserted in a deep ipsilateral forearm vein to obtain venous blood samples.
Effect of insulin on a-adrenergic responsiveness. First, after 30-min equilibration, baseline measurements were performed during concomitant intraarterial infusion of placebo (NaCl 0.9%, 50 | j l 1 • dl" 1 * min" 1). In 12 sub jects, NE (Centrapharm) was infused in six sequential ascending doses into the brachial artery. Each concentra tion was prepared separately so that infusion volume did not change. The doses were 1.25, 5, 2 0 , 80, 160, and 240 ng * dl" 1 ■ min" Second, after an interval of at least 1 month, the pro tocol was repeated in 9 of the 12 subjects, but without the concomitant infusion of propranolol, to study the effects of NE alone. Unfortunately, 3 subjects were not mea sured a second time: 1 refused a second measurement, 1 could not be cannulated again, and 1 could not be mea sured again due to lack of time. Because of these 3 drop outs, 3 other subjects were included in the second proto col to obtain a similar statistical power as in the first series.
Third, time control studies were made of a-adrenergic responsiveness. To exclude the possibility of down regu lation of a-adrenoceptor induced by the first infusion of multiple doses of NE, to correct for eventual systemic effects, and to exclude an effect of the time course and vehicle, control experiments were performed in 6 sub jects: NE was administered in six doses (similar to series I and II), first with placebo (NaCl 0.9%) and followed by a time period of saline + addition of autologous plasma (but not insulin); NE dose-response measurements were then repeated.
Effect o f insulin on p-adrenergic responsiveness. in 12 other subjects, an identical protocol was performed, but instead o f N E, ISO (isoproterenolsulfaat, 1 ml = 1 mg, RVG 51722 UR, Fresenius BV, 's-Hertogenbosch, The Netherlands), a pure (3-adrenoceptor agonist, was infused in six increasing dosages of 0.03, 0 . 1, 0.3, 1 .0 , 3.0 , and 10 ng • dl -l min -1 each dose for 5 min. After comple tion of the last dose, at least 45-min equilibration was allowed before repeated baseline measurements were performed. Insulin was then again infused into the bra chial artery in exactly the same way and dose as in the first two studies, but for 60 min before readministration of the six isoproterenol dosages.
Calculations and statistical analysis
All descriptive data are expressed as mean ± SD. FBF is expressed as ng ■ dl -1 min \ Furthermore, the ratio of blood flow in the infused arm as compared with that in the control arm was calculated for each FBF measure ment. According to the literature, presentation of the data as the ratio of the left and right FBF is the best way to correct for eventual systemic changes due to arousal or to systemic effects of drugs (28, 33) . Therefore, the FBF ra tio was chosen as the preferential parameter and calcu lated percentage change was used for comparison. Often, FBF at the experimental side is also indicated to illustrate obtained flows. Differences between baseline flow pa rameters and flows during local hyperinsulinemia were calculated by Student's paired t test.
The NE (± propranolol)/ISO dose-response curves ex pressed in percentage change in FBF ratio from baseline, before and during hyperinsulinemia, were evaluated by a tw o-factor repeated-m easures a n a ly sis o f variance (ANOVA) to assess the effects o f insulin, N E (± propranolol)/ISO and the interaction o f these agents. In the 9 subjects in whom two experiments were performed (once with and once without propranolol), the differences in the individual responses were used to calculate a (3-adrenoceptor-mediated vasodilator component of N E infusion. When data were pooled (effect of insulin/time), only the first obtained data set of subjects who were studied twice was used for evaluation.
A p-value <0.05 was considered statistically signifi cant, All statistical analyses were performed with the SPSS personal computer package. All results are mean ± SEM unless otherwise indicated,
RESULTS
Insulin and glucose concentrations during the study
During intraarterial infusion of insulin, deep ve nous forearm insulin concentration increased from 65 ± 22 to 498 ± 48 pM, indicating regional physi ological hyperinsulinemia. In contrast, arterial insu lin levels did not change. After 30 min of local in sulin administration, venous plasma glucose con centration was decreased from 4.6 ± 0.3 to 3.8 ± 0.6 mM, whereas arterial levels did not change (from 4.8 ± 0.3 to 4.7 ± 0.3 mM),
Effects of adrenergic stimulation on skeletal muscle blood flow
Regional infusion of propranolol in itself did not affect baseline flow (FBF ratio 1.08 ± 0.08 vs. 1,07 ± 0.09, p = NS). NE in combination with propran olol caused a dose-dependent decrease in flow (FBF ratio from 1.07 ± 0.09 to 0.22 ± 0.04, FBF from 1.7 ± 0.2 to 0.4 ±0.1 ml ■ d l""1 • min" 1 p < 0.001) (Fig. 1) . NE alone again induced a forearm vasoconstrictor response (FBF ratio from 1.12 ± 0.07 to 0.45 ± 0,07, FBF from 1.8 ± 0.2 to 0.8 ± 0.2 ml • dl" 1 ■ m in"1, p < 0.001 for both) that was ini tially dose dependent, but the response to the high- 6 . est N E dose (FBF ratio 0.52 ± 0 .1 1 , FBF 1.0 ± 0.3 ml • d l~l • m in~l) appeared to be less pronounced than that to the preceding dose. Moreover, the overall responses were smaller than those to NE in combination with propranolol ( Fig. 1) . In the 9 subjects who underwent both experi ments, the responses to NE alone were significantly different from those to propranolol (p < 0 .001). Fig. 2) . ISO induced a dose-dependent vasodi lation (FBF ratio from 0.90 ± 0.08 to 5.16 ± 0.65, FBF from 1.7 ± 0.3 to 8.1 ± 0.8 ml * dl-1 * min" 1, p < 0.001) (Fig. 1) , After this first series of vasoac tive drugs, flow parameters returned toward base line values: all data pooled (n -33)-FBF ratio 1.03 ± 0.04 and 1.11 ± 0.10 (p = 0.45), FBF 1.7 ± 0.1 and 1.9 ± 0,1 ml • dl-1 * min" 1 (p = 0.18), be fore and after vasoactive drugs, respectively.
Subtraction of the vasoconstrictor response to NE + propranolol and the response to N E alone showed a dose-dependent vasodilatory component in the effect of N E, presumed to be (3-adrenoceptor-mediated (it can be inhibited by propranolol) (34) (
Effects of insulin on skeletal muscle blood flow
In 27 subjects, insulin was locally infused as part of the protocol. After 30 min of regional hyperinsulinemia, an obvious increase in the FBF ratio (in fused/control arm) was observed from 1.16 ± 0.12 to 1.56 ± 0.15 (p = 0.009), FBF increased from 2.2 0.3 to 2.8 ± 0.4 ml ■ dl -1 min -1 (P 0 .002). Mean percentage increase in blood flow was 38 ± 11%, p = 0.001, with a wide range ( -23 to + 158%). In the subgroup of 9 subjects who had participated in both the N E alone and the NE in combination with propranolol experiments, there was no difference in the increase in FBF with insu lin alone, versus increase in FBF after previous pro pranolol administration (percentage increase 43 ± 17 vs. 50 ± 12%, without and with propranolol, respectively, p = 0 .68).
Effects of insulin on adrenergic responsiveness
Due to the previous insulin-induced vasodilator response, baseline parameters before the two sets of experiments were not equal. To correct for these differences and for possible nonspecific systemic changes, we calculated percentage changes of FBF ratios, according to the literature (28) (described in the Materials and Methods section).
Percentage changes in FBF ratio during NE + propranolol were similar and not significantly dif ferent before and during hyperinsulinemia (maxi mum percentage decrease 79.5 ± 3.0% before insu lin vs. 75.5 ± 4.0% during hyperinsulinemia, p = 0.25) (Fig. 3) .
Similar results were observed for the percentage changes of the FBF ratios during insulin and NE administration alone (maximum percentage de crease 55.7 ± 8.7% before insulin vs. 57.4 ± 3.8% during insulin, p = 0.81). In time control studies, as shown in Fig. 4, repeated imum percentage increase 524 ± vs. 441 ± 63% during insulin, p 88% before insulin = 0.19) (Fig. 5) .
DISCUSSION
We confirmed that insulin administered locally in physiological concentrations induces vasodilation in forearm skeletal muscle. Our results also show that hyperinsulinemia in the physiological range does not attenuate the forearm vasoconstrictor re sponse to NE or the vasodilatory response to ISO. This conclusion is based on the comparable per centage responses of FBF ratio before as compared with during insulin administration. Indeed, evalua tion of the absolute changes after drug infusion would have shown a more pronounced response during hyperinsulinemia. However, as reported previously (28), the absolute decrease in FBF dur ing administration of a vasoconstrictor is signifi cantly correlated to the level of the baseline FBF (correlations in our study between mean decrease in FBF during combined NE/propranolol and baseline flow: r = 0.76 before insulin and r = 0.93 during insulin). Because insulin increased the baseline FBF significantly, the subsequent absolute NEinduced decrease in FBF was also increased, but nonspecifically. This view is further supported by the study of Neahring and colleagues (20), who showed that the absolute but not the relative re sponse to intrabrachial NE infusion was increased by regional infusion of the vasodilator drug sodium nitroprusside.
Neither were the responses to the p-adrenoceptor-mediated vasodilator ISO affected by local hy perinsulinemia. With all these considerations taken into account, our data suggest that insulin in phys iological concentrations shows no specific interac tion with a-or (3-adrenergic-stimulating agents at the level of the forearm vascular bed.
Vasodilatory effect of insulin
In acute experiments in humans, systemic insulin infusion with maintenance of euglycemia exerted a vasodilator effect in skeletal muscle (9, 12, 35) . Al though controversial results have been reported af ter local insulin administration, recent reports mostly show a local vasodilatory effect as well (10, 36) . Two important aspects could explain part of the controversial findings. First, insulin-induced vasodilation apparently is not an acute effect, but instead is one of slow onset. Steinberg and associ ates infused insulin into the femoral artery and re ported a significant increase in femoral blood flow after 20 min but not after 10 min of infusion (37) . We noted a clear increase in FBF after 30 min. In the group receiving ISO, insulin was infused for 60 min, but FBF did not increase from 30 to 60 min. Sec ond, the individual vasodilator response to insulin shows a high variability, in our study ranging from -2 3 to 4-158%, as has been reported by other in vestigators (10). This indicates that in studies with small sample sizes the effect could be missed due to a type 2 statistical error. Because of the many par ticipants, the insulin-induced vasodilation was highly significant in the current study. 
Effect of insulin on a-adrenoceptor-mediated vasoconstriction Several reports have shown very controversial findings with regard to the effect of insulin on a-adrenoceptor-mediated vasoconstriction. Results of several recent studies in vivo in humans, compara ble to ours, appear to be in contrast to our findings. Sakai and co-workers (18) did not observe a signif icant vasodilator effect of insulin infusion but re ported an attenuated a-adrenoceptor stimulation by
Effect of insulin on P-adrenoceptor-mediated vasodilation Recent in vitro experiments have shown an insulin-mediated enhancement of vascular (3-adrenergic responsiveness to ISO (24)
. On the other hand, im paired forearm |3-adrenoceptor-mediated vasodila tion to isoproterenol has been described in patients with hypertension (25) . Our experiments quite con vincingly show that acute local physiological hyper insulinemia in the human forearm vascular bed does not influence the sensitivity to the (5-adrenoceptor agonist isoproterenol. In addition, we provide fur ther indirect evidence for these findings: Our exper iments were performed with the endogenous neuro transmitter NE instead of PE or related a-adrenoceptor agonists, especially because it is the most physiological method of investigating the effect of insulin on a-adrenoceptor sensitivity. However NE can induce (3-adrenoceptor-mediated vasodilation and also has vasoconstrictor properties (34,38). To study the pure a-effect, we performed the study twice, once with and once without a (3-adrenoceptor blocking agent. The last study was also performed to exclude an effect of insulin which could have been (3-adrenoceptor mediated, an effect that has been reported previously (39) . By comparing the paired studies with and without propranolol, we were able to confirm the dose-dependent (13adrenoceptor-mediated) vasodilator component of NE and were also able to confirm that this vasodi lator component was not influenced by regional hy perinsulinemia.
This finding further supports our conclusion that the vascular effects of the endogenous neurotrans mitter NE are not altered by increased insulin con centrations. Moreover, our results further show that the addition of a (3-adrenoceptor blocking agent is essential when N E is used to study pure a-adrenoceptor-mediated effects. Therefore, our results appear to be significant because most studies of the interaction between insulin and N E did not correct for eventual fi-adrenoceptor-mediated effects of NE (14-17,20,21).
We confirmed that regional infusion of insulin in duced a unilateral increase in FBF, indicating a lo cal mechanism. The mechanism of action of this direct vasodilator effect of insulin is not completely clear (40), but our results indicate that it is not re lated to modulation of a-or ^-adrenergic respon siveness. Other mechanisms probably are involved; recent reports indicate a nitric oxide-dependent pathway (37,41).
